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At least two types of animal plasminogen actlvatmg enzymes exist, differing in amino acid sequence, 
molecular mass and Immunological reactivity: the urokinase-type and the tissue-type plasmmogen 
activators. By affinity chromatography with monoclonal antlboches, we have purified the human 
activators of both types to homogeneity. Using immunocytochemistry with rabbit antibodies raised against 
these preparations, we now demonstrate hat the plasminogen activator present in endothelium of veins 
and other blood vessels i  of the tissue-type. No urokinase-type lasminogen activator immunoreactivity 
was detected in endothelial cells in the intact organism. These findings support he assumption that 
moblllzatlon of plasmm for different purposes may involve different ypes of plasminogen activators, and 
that the plasminogen activator involved in thrombolysis of the tissue-type. 
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1. INTRODUCTION 
Activation of plasminogen to the trypsin-like 
protease plasmin is a general mechanism for pro- 
ducing localized extracellular proteolysis [ 11. This 
activation is implicated in a variety of processes, 
including thrombolysis [2], ovulation [3], embryo 
implantation [4], the conversion of prohormones 
[5], cell migration [a], tissue remodelling [7], and 
tissue degradation in a number of normal as well 
as pathological conditions [8- 121. 
urokinase-type (u-PA) has M -52000 and the 
tissue-type (t-PA) enzyme A& -66000. Con- 
tributing to the functional diversity of plasmin- 
mediated proteolysis might be that some processes 
involve activation of plasminogen by one type of 
activator while other processes involve activation 
by the other type. This study was undertaken to 
elucidate whether one or both types of activators 
are involved in thrombolysis. 
Two types of mammalian plasminogen ac- 
tivators, differing in M,, amino acid sequence and 
immunological reactivity, have been purified and 
characterized [ 10,13-231. In humans, the 
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We have raised monoclonal antibodies against 
both types of plasminogen activators [20,22]. In 
cultured cells [24] and in a paper model system 
[25], in which spots of enzyme were stained, using 
peroxidase-conjugated second antibodies, we 
found that the monoclonal antibodies were less 
suited for the staining of fixed enzymes. The 
monoclonal antibodies were therefore used to pro- 
duce highly purified enzyme preparations which, 
in turn, were used to raise polyclonal rabbit an- 
tibodies. In the paper model system, the polyclonal 
antibodies stained pure paraformaldehyde fixed 
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preparations of the respective nzymes with a high 
affinity, and we now report that endotheii~ cells 
of blood vessels in the intact organism contain t- 
PA but not detectable amounts of u-PA. 
2. MATERIALS AND METHODS 
t-PA from the culture fluid of Bowes melanoma 
cells and u-PA from a commercial urokinase 
preparation (Leo Pharmaceuticals, Copenhagen) 
were purified to homogeneity, as evaluated by 
SDS-polyacrylamide gel electrophoresis, by af- 
finity chromatography with monoclonal anti- 
bodies [18,22]. Rabbit antibodies were raised by 
intradermal injection of approx. 1Opg of the 
respective enzymes inhibited by diisopropylfluoro- 
phosphate following the scheme in [15]. The rab- 
bits were bled and the indi~dual sera were com- 
pared using immunocytochemical paper models 
[25]. From the sera selected by this method, IgG 
was purified by affinity chromatography on pro- 
tein A-Sepharose. Dilutions for immunoc~~he- 
mistry were made in TBS-BSA rO.05 M Tris- 
HCl (pH 7.4) 0.15 M NaCl, 0.25~0 bovine serum 
albumin]. Abdominal and breast skin, obtained 
from patients undergoing plastic surgery, was im- 
mediately frozen in isopentane on dry-ice. 
Cryostat sections were thawed at 4°C in 0.1 M 
phosphate buffer (pH 7.4) containing 4% para- 
form~dehyde, washed in TBS-Triton [O-O5 M 
Tris-HCI (pH 7.4), 0.15 M NaCl with 1% Triton 
X-100], exposed to normal swine serum and in- 
Fig.1. Demonstration of human tissue-type plasminogen activator (t-PA) in endothelial cells of human skin. (a) 
Micrograph showing the staining of endothelial cells of veins and small vessels, and the lack of staining arteries of 
human breast skin, with anti-t-PA IgG (1 &ml, BSA absorbed); x 104. (b) Staining of ~dotheli~ cells of vessels in 
human abdominal skin with anti-t-PA IgG (1.5 @g/ml); x 82, (c) Staining of endothelial cells of a vein in human 
abdominal skin with anti-t-PA IgG (1 &ml, BSA absorbed); x 203. (d) Staining of section adjacent to (c) with anti-t- 
PA IgG (1 @g/ml) absorbed with highly purified t-PA (see text); x 203. (e) Staining of vessels in human breast skin 
with anti-t-PA IgG (I pg/ml, BSA absorbed); x 104. (f) Enlargement of section (e); x 260. 
34 
Volume 168, number 1 FEBS LETTERS March 1984 
cubated overnight at 4’C with the primary an- 
tibody. The site of antigen-antibody reaction was 
revealed with the pero~dase-antiperoxidase 
method in 1261, and the peroxidase activity was 
demonstrated with diaminobenzidine-Hz02 
[26,27]. Rabbit antiperoxidase-peroxidase com- 
plexes and swine anti-rabbit IgG were from 
Dakopatts, Copenhagen. All washings of sections 
were performed with TBS-Triton, and sections 
were lightly counterstained with haematoxylin- 
eosin or a.m. van Gieson. Control experiments 
[26,27] included: (i) omission of either the first, se- 
cond or third layer of antibody; (ii) substitution of 
anti-t-PA antibody with non-immune rabbit IgG; 
(iii) abso~tion of anti-t-PA antibody with highly 
purified t-PA, bovine serum albumin or urokinase, 
each coupled to Sepharose. Staining and controls 
were performed on adjacent sections using the 
same concentrations of IgG. 
3. RESULTS 
In the paper model system, the polyclonal an- 
tibodies stained pure paraformaldehyde fixed 
preparations of the respective nzymes with a high 
affinity, which was approximately the same in the 
two cases; there was no cross-reaction between the 
antibodies directed against the two enzymes. 
In human skin, the anti-t-PA IgG (1 pg/ml) 
stained endothelial cells of veins and of some, but 
not all, smaller arteries (fig.1). The presence or 
absence of staining of endotheli~ of the muscular 
arteries could not be correlated with either the site 
or the size of the artery. In addition, staining was 
found in a number of small vessels evenly 
distributed in the dermis. Counterstaining by van 
Gieson demonstrated muscle cells surrounding 
these vessels, which thus could represent small 
arterioles or precapillary sphincters, but not 
capillaries. 
Staining of human gastric mucosa and lung with 
anti-t-PA showed a staining distribution in the en- 
dothelial cells of vessels imilar to that found in the 
skin (not shown). 
Control experiments demonstrated absence of 
staining after omission of any of the antibody 
layers, substitution with non-immune IgG or pre- 
absorption of anti-t-PA IgG with purified t-PA. 
Staining was unchanged after absorption of anti-t- 
PA IgG with bovine serum albumin and urokinase. 
No staining of endothelial cells was observed 
with anti-u-PA in concentrations up to 50/sg/ml, 
either in skin, gastric mucosa or lung. As judged 
from the paper cytochemical models, this concen- 
tration of anti-u-PA could detect u-PA if the 
amount of this enzyme present in the endothelial 
cells was at least 5% of that of t-PA. Thus, our 
findings indicate that, of the two types of 
pl~~nogen activators, the endotheli~ cells in the 
intact organism contain mainly or exclusively t- 
PA. 
4. DISCUSSION 
To our knowledge, this report represents the 
first immunocytochemical study of t-PA. Plas- 
minogen activators are present in very small con- 
centrations, and immunocytochemical studies de- 
pend on highly purified enzyme preparations for 
raising antibodies of sufficient strength and speci- 
ficity. Af~~ty chromato~aphy with monoclon~ 
antibodies offers an efficient method to obtain 
such highly purified enzyme preparations 
[18,20,22]. 
The lack of detectable u-PA immunoreactivity 
in human endothelial cells is in agreement with a 
recently reported study of the ~st~bution of u-PA 
immunoreactivity in the mouse [28]. Immunoreac- 
tivity was found in several cell types, but no im- 
munoreactivity was observed in any endothelial 
cells. 
Previous investigations of the type of plas- 
minogen activator present in endotherm cells have 
led to apparently conflicting results. Authors in 
[29] reported that cultured bovine endothelial cells 
synthesized both u-PA and t-PA, while those in 
[30] found that only antibodies to t-PA, and not 
antibodies to u-PA, inhibits plasminogen ac- 
tivator activity in human endothelium in tissue sec- 
tions, as measured by the fibrin overlay method 
described in [31]. The studies in [30], however, did 
not exclude that the endothelium still contained 
considerable amounts of u-PA, because the fibrin 
overlay method preferenti~ly may detect t-PA, as 
it is known that the activity of t-PA, in contrast to 
u-PA, is greatly enhanced by fibrin [32,33]. The 
present study shows that also on a molar basis the 
endothelial cells in the intact organism mainly con- 
tain t-PA and no demonstrable amounts of u-PA. 
The apparent discrepancy with the results in [29] 
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may be due to the fact that cultured cells are not 
necessarily representative of cells in the intact 
organism with respect to plasminogen activator 
synthesis. 
Our results support the assumption that t-PA, 
and not u-PA, is involved in thrombolysis, in 
agreement with reports that in experimental 
systems t-PA is more effective than u-PA as a 
thrombolytic agent [34,35]. The findings thus also 
lend support to the assumption that the mobiliza- 
tion of plasmin for different purposes can involve 
different types of plasminogen activators. 
It is noteworthy that, among human plas- 
minogen activators, mainly u-PA has been used 
clinically in thrombolytic therapy [36] and that the 
success of this therapy has only been moderate. It 
seems likely that t-PA will prove to be more effec- 
tive for this purpose than u-PA. 
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